ENLON PLUS SUMMARY
ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, for intravenous use, is a sterile, nonpyrogenic, nondepolarizing neuromuscular relaxant antagonist. ENLON-PLUS is a combination drug containing a rapid acting acetylcholinesterase inhibitor, edrophonium chloride, and an anticholinergic, atropine sulfate.
Enlon Plus (Edrophonium/Atropine) is indicated for the following:
ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.
The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition.
Clinical Trials Related to Enlon Plus (Edrophonium / Atropine)
Measurement of Autonomic Cardiovascular Integrity in Persons With SCI [Recruiting]
People with a spinal cord injury (SCI) have limited ability to move and feel sensation below
the level of the SCI. Doctors and researchers have tests which determine the level of
function and sensation, this test was developed by the American Spinal Cord Injury
Association (ASIA) and has been modified over the years to improve use and sensitivity.
Most recently, the ASIA Injury classification Scale (AIS) was modified in 2011, but this
test does not include the evaluation of autonomic nervous system (ANS) impairment. However,
people with SCI do have impairment of the ANS and this may adversely affect how organ
systems in the body function. Specifically, ANS impairment tends to result in changes in
heart rate and blood pressure that may relate to the level of the SCI, but this is not fully
understood. In this investigation we hope to develop simple tests which will allow doctors
and scientist the ability to measure the amount of ANS impairment to the cardiovascular
system, specifically the heart. The first part of the study will be to determine the heart
rate response to several tests (administration of drugs and physical challenges) which will
change heart rate. These tests will be given to people with and without SCI and the heart
rate response will be compared between people with and without SCI. The bigger the
difference in the heart rate response to these test between people with and without SCI the
greater degree of ANS impairment in the people with SCI. Once this heart rate difference is
determined, several simple tests (deep breathing, saliva test, Valsalva) will be performed
in people with and without SCI to again compare the heart rate response. The second part of
this study will be to determine if the heart rate responses to the first set of tests
(administration of drugs and physical challenges) can predict the heart rate response to
these simple tests (deep breathing, saliva test, Valsalva). The aim of this study is to
develop a simple battery of tests which can be easily used by doctors and scientists to
determine the degree of ANS impairment to the heart in persons with SCI.
Page last updated: 2009-11-25